Others have shown that inactivating mutations in HSD17β13 protect humans from MASLD (14, 44), yet Hsd17β13 deficiency in mice did not reproduce the protective role of HSD17β13 loss-of-function mutants (27). This evidence concerns the gene HSD17B13 and metabolic dysfunction-associated steatotic liver disease.